Discontinued — last reported Q4 '25
Morgan Stanley Interest Paid increased by 14.3% to $14.20B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 13.9%, from $12.46B to $14.20B. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 145.2% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $295.00M | $355.00M | $67.00M | $623.00M | $784.00M | $2.93B | $5.48B | $8.91B | $10.25B | $11.14B | $11.64B | $11.88B | $11.14B | $11.48B | $11.86B | $12.46B | $12.08B | $10.14B | $12.41B | $14.20B |
| QoQ Change | — | +20.3% | -81.1% | +829.9% | +25.8% | +274.0% | +86.9% | +62.6% | +15.0% | +8.7% | +4.5% | +2.0% | -6.2% | +3.0% | +3.3% | +5.1% | -3.1% | -16.1% | +22.4% | +14.3% |
| YoY Change | — | — | — | — | +165.8% | +725.9% | >999% | >999% | >999% | +279.8% | +112.4% | +33.3% | +8.7% | +3.1% | +1.9% | +4.9% | +8.4% | -11.7% | +4.7% | +13.9% |